Targeted biopsy-only detection rates for Grade Group ≥2 were 38% with microultrasonography, 34% with MRI/US-fusion (P=0.003 for noninferiority), and 40% with microultrasonography/MRI (P<0.001 ...

NEW YORK. (KFSN) -- For decades, doctors have diagnosed prostate cancer using what's been called a 'blind' biopsy, removing and testing a dozen tiny tissue samples to see if cancer is present. Now ...

3.5 The committee considered that adopting MRI fusion biopsy systems could prolong waiting time for prostate biopsies, and that this was not captured in the cost-effectiveness estimates. The clinical ...

(HealthDay)—Magnetic resonance imaging-ultrasound fusion targeted prostate biopsy (MRF-TB) improves detection and risk stratification of high-grade disease and limits detection of clinically ...

Magnetic resonance imaging (MRI)/fusion targeted prostate biopsy may improve detection of clinically significant tumors in prostate cancer patients on active surveillance (AS) undergoing ...

Among nearly 18,000 participants, 0.6% of men who underwent MRI-targeted biopsy alone were diagnosed with clinically insignificant prostate cancer (Gleason 3+3) compared with 1.2% of those in a ...

TOPLINE: High-resolution microultrasonography-guided biopsy was non-inferior to MRI fusion-guided biopsy for detecting clinically significant prostate cancer (detection rates, 47.1% and 42.6% ...

A new screening technology fusing MRI with real-time 3D ultrasound has been developed by scientists. This provided an exacting method to obtain biopsy specimens from suspicious areas in the prostate.

A team of UCLA expertshas introduced refinements to targeted biopsy of prostate cancer, greatly improving the ability to distinguish men who should have treatment from those who could defer.

With targeted MRI/ultrasound and the ARTEMIS 3D Semi-Robotic Prostate Fusion Biopsy System technology available at Palm Beach Gardens Medical Center, the urology team is able to better identify ...

Targeted biopsy-only detection rates for Grade Group ≥2 were 38% with microultrasonography, 34% with MRI/US-fusion (P=0.003 for noninferiority), and 40% with microultrasonography/MRI (P<0.001 ...

2.7 The Artemis fusion biopsy system (InnoMedicus Artemis) includes a semi-robotic mechanical arm and a mobile workstation. The system uses ProFuse radiology software for preparing MRI data for fusion ...